Obstructive sleep apnea (OSA) may represent a treatable secondary cause of hypertension 1 with epidemiological studies identifying both a significant linear increase in daytime blood pressure (BP) with increasing apnea-hypopnea index (AHI) 2,3 and a remarkably high prevalence of OSA in drug-resistant hypertension (RH) ranging from 56 to 85%, depending on the criteria used. 4-6 Several, 7-9 although not all, 10 cross-sectional and prospective cohort studies have demonstrated an association between short, self-reported or actigraphically estimated, sleep duration and the prevalence and incidence of hypertension or prehypertension even after controlling for other risk factors. However, neither of these studies measured sleep time objectively nor assessed for the presence of other sleep disorders, such as OSA, that could also disrupt and shorten sleep, and thus confound any apparent relationship between short sleep time per se and elevated BP. 11 We recently reported a significantly higher prevalence of OSA and reduced rapid eye movement (REM) sleep time in patients with RH compared to those with controlled hypertension (CH). 12 Because of the higher AHI in the RH patients, it remained unclear whether the shortened REM sleep duration contributed to the severity of hypertension independently of OSA.
Obstructive sleep apnea (OSA) may represent a treatable secondary cause of hypertension 1 with epidemiological studies identifying both a significant linear increase in daytime blood pressure (BP) with increasing apnea-hypopnea index (AHI) 2, 3 and a remarkably high prevalence of OSA in drug-resistant hypertension (RH) ranging from 56 to 85%, depending on the criteria used. [4] [5] [6] Several, [7] [8] [9] although not all, 10 cross-sectional and prospective cohort studies have demonstrated an association between short, self-reported or actigraphically estimated, sleep duration and the prevalence and incidence of hypertension or prehypertension even after controlling for other risk factors. However, neither of these studies measured sleep time objectively nor assessed for the presence of other sleep disorders, such as OSA, that could also disrupt and shorten sleep, and thus confound any apparent relationship between short sleep time per se and elevated BP. 11 We recently reported a significantly higher prevalence of OSA and reduced rapid eye movement (REM) sleep time in patients with RH compared to those with controlled hypertension (CH). 12 Because of the higher AHI in the RH patients, it remained unclear whether the shortened REM sleep duration contributed to the severity of hypertension independently of OSA.
Experimentally induced sleep deprivation can elevate arterial pressure and worsen hypertension in humans and in animals, [13] [14] [15] [16] suggesting that sleep restriction can raise BP. It is therefore possible that shortened sleep time, independent of the disrupting effects of OSA on normal sleep architecture, may be related to RH. Accordingly, this study was undertaken to examine whether short total and REM sleep times are associated with RH, independently of OSA. In this study, we compared sleep times and stages during attended overnight polysomnography between RH patients with OSA, and CH and normotensive (NT) patients with equally severe OSA. 
Background
Experimentally induced sleep deprivation can raise blood pressure (BP) and worsen hypertension. We recently reported a significantly higher prevalence of obstructive sleep apnea (OSA) and reduced rapid eye movement (REM) sleep time in drug-resistant hypertensives compared to controlled hypertensives. The objective of this study was to test the hypothesis that short sleep duration is associated with resistant hypertension (RH) independently of OSA, which can itself disrupt and shorten sleep.
Methods
In a case-control study, overnight polysomnographic results of subjects with OSA and RH (n = 62) were compared to those with OSA of equal severity and either controlled hypertension (CH) (n = 49) or normotension (n = 40).
results
Subjects with RH slept 33.8 min (P = 0.02) and 37.2 min (P = 0.02) less than those with CH and normotension, respectively. Consequently, sleep efficiency was reduced by 7.9% (P = 0.007) and 10.2% (P = 0.002), respectively. They also spent 9.7 min (P = 0.06) and 11.6 min (P = 0.04) less time in REM sleep compared to those with CH and normotension, respectively. Older age, greater body mass index (BMI) and greater apnea-hypopnea index (AHI) were also associated with shorter sleep time (P = 0.02, P = 0.001, and P = 0.03, respectively) and reduced sleep efficiency (P = 0.0003, P = 0.03, and P = 0.01, respectively).
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Methods
Study design. We employed a case-control study design to compare the sleep quantity and architecture of subjects with RH and coexisting OSA to those with either CH or NT matched for severity of OSA to the RH group. The Human Subjects Review Committee of the University of Toronto and the Research Ethics Board of Mount Sinai Hospital (Toronto, Canada) approved the study. All subjects provided written informed consent prior to participation.
Subjects. Subjects with RH were identified by reviewing the charts of patients in the Mount Sinai Hospital Hypertension Clinic who underwent investigations to determine the causes of hypertension that were apparently resistant to medical therapy. RH was defined as a clinic BP ≥140/90 mm Hg and a daytime BP ≥135/85 mm Hg on 24-h ambulatory BP monitoring while adherent to ≥3 antihypertensive medications at maximal or near-maximal doses including a diuretic, unless contraindicated or intolerant, or as a BP below these levels while on ≥4 antihypertensive medications. 17 Subjects received instructions to reduce dietary sodium intake to the level recommended for hypertensive patients. 18 Individuals were excluded if they reported poor medication adherence, 19 had a secondary cause of hypertension (including chronic kidney disease defined as a serum creatinine of >150 µmol/l), ingested exogenous substances that could raise BP, had a history of alcohol abuse 20 or elevated aminotransferase levels more than twice the upper limit of normal, or had hemodynamically significant aortic or mitral valve disease. Consecutive subjects were sent for overnight polysomnography irrespective of symptoms suggestive of OSA. Those found to have OSA with an AHI ≥10 were included in the analysis.
CH was defined as a clinic BP <140/90 mm Hg and a daytime BP <135/85 mm Hg on ambulatory BP monitoring whereas on ≤3 antihypertensive medications. We reviewed the charts of CH patients who were seen during the same time as those with RH. Patients with CH similar in sex distribution and body mass index (BMI) to the RH group then underwent overnight polysomnography irrespective of symptoms suggestive of OSA, and those found to have OSA with an AHI ≥10 were included in the analysis.
NT was defined as a clinic BP <140/90 mm Hg while on no antihypertensive medications. NT patients were identified from chart review of the Sleep Disorders Clinic of The Toronto General Hospital of the University Health Network who were seen during the same time period as those with RH. Consecutive patients found to have OSA with an AHI ≥10 and with similar sex distribution and BMI to the RH group were included in the analysis. In determining the number of antihypertensive medications, dihydropyridine and nondihydropyridine calcium channel blockers were considered as two separate drugs as were diuretics with actions on different nephron sites. BMI was calculated as weight in kilograms divided by the square of height in meter.
Ambulatory BP monitoring. Prior to polysomnography, ambulatory BP monitoring was performed for 24 h in subjects with RH and CH using an automated sphygmomanometer (SL-90207; SpaceLabs Medical, Redmond, WA). An appropriate sized cuff was fitted to the nondominant arm with BP measured every 20 min during the wake period and every 30 min during the sleep period. Subjects recorded the times when they retired at night and awoke in the morning.
Polysomnography. Full-night diagnostic polysomnography was performed in all subjects using standard techniques and scoring of sleep stages and arousals 21, 22 to determine precisely the onset, duration and stages of sleep. None of the subjects received sedative-hypnotic agents to induce sleep on the night of the sleep study. Sleep efficiency was calculated as total sleep time expressed as a percentage of the time spent in bed after lights out. Among subjects with RH and CH, the technicians performing the sleep studies were blinded to the BP status of the subjects. Thoracoabdominal movements and tidal volume (V T ) were monitored by a calibrated respiratory inductance plethysmograph (Respitrace; Ambulatory Monitoring, White Plains, NY). Oxyhemoglobin saturation (SaO 2 ) was continuously monitored by a pulse oximeter (Nellcor N-200 pulse oximeter; Nellcor, Hayward, CA) and recorded on a computerized sleep scoring system (Sandman, Nellcor Puritan Bennett, Ottawa, Ontario, Canada). The mean and minimum SaO 2 during sleep were recorded as previously described. 23 Apneas were defined as an absence of a V T excursion for >10 s and were classified as obstructive if there was out-of-phase thoracoabdominal motion and as central if there was no thoracoabdominal motion. Hypopneas were defined as a >50% reduction in V T excursion but above 0 for >10 s and were classified as obstructive if there was out-of-phase thoracoabdominal motion and as central if thoracoabdominal motion was in phase. 5, 24 The frequency of apneas and hypopneas per hour of sleep was expressed as the AHI and OSA was defined as an AHI ≥10. 5, 24 This cutoff was used to conform to our previous studies, and because we have shown that treatment of OSA above this AHI cutoff in patients with coexisting RH is accompanied by a reduction in BP. 5, 12, 24 Statistical analysis. Continuous variables were expressed as means ± s.d. whereas categorical variables were expressed as proportions. One-way analysis of variance with Bonferroni post hoc correction for multiple comparisons was used to test for differences in continuous variables across BP status; the unpaired t-test was used to compare the number of antihypertensive drugs between the two hypertensive groups. Pearson's χ 2 -test or Fisher's exact test, as appropriate, were utilized to compare categorical variables across BP status followed by decomposition, where indicated. 25 Analysis of covariance was employed to determine whether differences in sleep variables were independent of potential confounding factors including age, sex, BMI, AHI, and diabetes. We also performed tests for interactions between BP status and antihypertensive drug class including angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, β-blocker, calcium channel blocker, and diuretic. A two-tailed P value of <0.05 was considered original contributions Sleep Duration and Resistant Hypertension statistically significant. All analyses were conducted using SAS, version 9.1.3 (SAS Institute, Cary, NC).
results characteristics of the subjects
We identified 62 subjects with RH and OSA, and 49 subjects with CH and 40 subjects with NT matched for severity of OSA. Subjects with RH and CH were significantly older than those with NT (P = 0.002 and P = 0.007, respectively) but the groups were similar with respect to sex and BMI ( Table 1) . By design, the AHI was similar in the three groups. Diabetes was more prevalent among subjects with RH than those with NT (P = 0.01). By definition, office and 24-h BP values were higher in the RH group (P < 0.0001) despite a greater number of antihypertensive drugs (P < 0.0001).
Polysomnographic variables
Analyses adjusted for differences in age, sex, BMI, AHI, and diabetes between the groups demonstrated a shorter total sleep time among subjects with RH by 33.8 min (P = 0.02) and 37.2 min (P = 0.02) compared to subjects with CH and NT, respectively ( Table 2) . This was associated with a reduction in sleep efficiency of 7.9% (P = 0.007) and 10.2% (P = 0.002) compared to subjects with CH or NT, respectively. There were also significant negative linear trends in total sleep time (P = 0.01) and sleep efficiency (P = 0.001) across the ordered categories of NT, CH, and RH. This was due to nonsignificant tendencies for both shorter stage 2 and REM sleep times by 19.5 min (P = 0.08) and 9.7 min (P = 0.06), respectively compared to subjects with CH, and to significantly shorter stage 2 and REM sleep times by 26.9 min (P = 0.03) and 11.6 min (P = 0.04), respectively compared to subjects with NT (Figure 1 ). There were no significant modifications of the foregoing associations with BP status according to use of any of the antihypertensive drug classes (data not shown).
The determinants of total sleep time and sleep efficiency are shown in Table 3 . Age, BMI, and AHI were negatively associated with total sleep time at −1.4 min/year (P = 0.02), −3.5 min/ kg/m 2 (P = 0.001), and −0.8 min/event/h (P = 0.03), original contributions
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respectively. Similarly, age, BMI, and AHI were also negatively associated with sleep efficiency at −0.4%/year (P = 0.0003), −0.5%/kg/m 2 (P = 0.03), and −0.17%/event/h (P = 0.01), respectively. Furthermore, compared to women, men had a significantly higher sleep efficiency of 6.7% (P = 0.02), and tended to have a longer total sleep time by 27.4 min (P = 0.056).
discussion
This case-control study demonstrates that subjects with RH have shorter total sleep time and lower sleep efficiency than subjects with CH or NT after controlling for the presence and severity of OSA, and after adjusting for differences in demographic, anthropometric, and medical factors among the groups. RH patients slept an average of only 4 h and 37 min, which was 34 min less than the CH group and 37 min less than the NT group. Our finding of a trend toward reduced REM sleep time in patients with RH compared to those with CH is consistent with that of our previous study, 12 and the significant reduction compared to NT subjects is an original finding. We also made the novel observation that stage 2 sleep was significantly shorter in the RH than in the NT group, and tended to be shorter than in the CH group. These observations raise the possibility that reduced total, stage 2 and REM sleep times, and sleep efficiency may play a role in the development of RH independently of the effects of OSA and arousals from sleep. A number of interventional studies have reported that acute partial or complete sleep deprivation can raise BP in subjects with NT and untreated hypertension. 14, 16, 26 In animal studies, prolonged REM sleep deprivation induces sustained hypertension in genetically predisposed rats, 13 and mice exposed to disturbed diurnal rhythm exhibit increased BP, reduced myocardial contractility and left ventricular dilatation. 27 Other studies in healthy young men have shown that short-term sleep deprivation impairs glucose tolerance and raises evening cortisol concentrations. 28 It is therefore noteworthy that the RH patients in our study were significantly more likely to have diabetes mellitus than NT subjects, and also had a similar, but nonsignificant, trend for a higher prevalence of diabetes mellitus than in the CH group, despite the three groups having a similar BMI, severity of OSA, and frequency of arousals from sleep.
The mechanism(s) accounting for the association of RH with short sleep time and reduced sleep efficiency remains unknown. One possibility is that sleep deprivation increases sympathetic nervous system activity that could raise BP. However, while some studies report increased sympathetic nervous system 30 increased endothelin levels, 31 reduced glucose tolerance, 28 or reduced flow-mediated endothelium-dependent vasodilatation and intracellular magnesium levels. 32 Our study is subject to a number of limitations. The observational nature of our study does not allow us to establish a cause-effect relationship between short sleep time and sleep efficiency, and RH. Despite adjusting for age, sex, BMI, AHI, and diabetes, there may have been an uneven distribution of other potential confounding factors associated with both RH and sleep time or sleep efficiency that were not assessed. Theoretically, it remains possible that specific antihypertensive drug classes may adversely affect sleep time. Nevertheless, there were no significant interactions between BP status and antihypertensive drug class; for example, the adjusted total sleep times in our hypertensive patients who were or were not prescribed β-blockers (283.9 min vs. 291.3 min, P = 0.23) or diuretics (285.9 min vs. 278.7 min, P = 0.66) were similar. Further, none of the subjects with RH were prescribed a central sympatholytic agent. Unlike a cohort study, temporality could not be established on the basis of our case-control study design such that we cannot exclude the possibility that RH contributes to short sleep time. However, this seems unlikely in view of long-term prospective data demonstrating that short self-reported sleep times are associated with increased risk of developing new onset hypertension, 7 and that short-term sleep deprivation raises BP. [14] [15] [16] In conclusion, we have demonstrated that in patients with OSA, RH is associated with shorter total sleep time and lower sleep efficiency than in subjects with CH and NT who have equally severe OSA and sleep fragmentation, that is due to shorter stage 2 and REM sleep times. These data, therefore, suggest that short sleep time increases the risk of RH independently of the presence of OSA, and other potential confounding factors. Such observations extend those of our previous study in which we reported that RH was independently associated with the presence of OSA and reduced REM sleep time, with only a trend toward reduced total sleep time compared to those with CH. 12 Taken together, our previous and the present studies suggest that RH is associated both with OSA and with reduced sleep times and sleep efficiency compared to patients either with CH or NT independently of other risk factors. This underscores the possibility that short sleep time and poor sleep efficiency may contribute to the pathogenesis of RH through mechanisms yet to be identified. Parenthetically, several prospective cohort studies also demonstrate independent associations between similarly short self-reported sleep durations and mortality 33, 34 as well as the occurrence of cardiovascular events. 35 However, whether modifying sleep time to some optimal level could translate into an improvement of BP and/or a reduction in the burden of cardiovascular disease among subjects with RH and OSA remains to be seen.
